Development status

ODR001 (in vitro derived platelets)

Finished product Platelets in suspension, generated from in vitro derived megakaryocytes through a microfluidic system
Primary indication Treatment of thrombocytopenia in patients at risk of bleeding or with bleeding events
Development status Pre-clinical stage

Clinical development path will be discussed with Health Authorities, based on existing guidelines.

ODR001 efficacy will be assessed in clinical trials planned to start in 2017.